Jonathan Corcoran

“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development,”

Jonathan Corcoran · said date not stated · reported 2026-11-03

Professor Corcoran commented on KCL-286's successful Phase 1 human safety trials and its potential to shorten drug development timelines.

“DNA double-strand breaks are like a rope snapping completely in two, rather than just fraying at the edges. We found that KCL-286 promotes repair of these breaks, allowing us to target a key feature of Alzheimer's disease,”

Jonathan Corcoran · said date not stated · reported 2026-11-03

Professor Corcoran explained that KCL-286 promotes repair of DNA double-strand breaks, a key feature of Alzheimer's disease.